A Phase 2 Study of XmAb 20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer

Brief description of study

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of XmAb20717 in patients with selected advanced gynecologic and genitourinary malignancies.


Clinical Study Identifier: s22-00496
ClinicalTrials.gov Identifier: NCT05032040
Principal Investigator: David R. Wise.
Other Investigators: Kathleen M Lutz, Fabia Brisard Pierrot, Christina Grace Wilson, Minas Platon Economides, Kent Chan, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Marina Stasenko, Edward A Jimenez, Erin Annette Reese, Bhavana Pothuri, Scot Niglio, Victor Ricardo Adorno Febles, Whitfield B. Growdon, Deanna Gerber, Caitlin Elizabeth Ryan, Kelly A Levine, Olivia Richardson Khouri, Hank Ng, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.